Coleman Mark 4

What Happened

• Mark Coleman, a director of Axsome Therapeutics (AXSM), had 1,429 restricted stock units (RSUs) vest and convert into common stock on June 8, 2026. Some of those shares were withheld/treated as a zero-dollar disposition to satisfy tax withholding. On June 10, 2026, Coleman sold 643 shares in the open market for total proceeds of approximately $160,107 (weighted average price $249.00). The sale was executed under a pre-approved 10b5-1 plan.

Key Details

• Dates and prices:
  • June 8, 2026: 1,429 RSUs vested and converted to 1,429 shares (transaction code M).
  • June 8, 2026: 1,429 shares were recorded as disposed at $0.00 to satisfy tax withholding related to the RSU settlement (disposition code M / tax withholding).
  • June 10, 2026: 643 shares sold in open market (code S) for a weighted average price of $249.00; proceeds ≈ $160,107. Sale prices in the series ranged $245.17–$253.04.
• The June 10 sale was pursuant to a pre-approved 10b5-1 trading plan, which the filing notes is now complete.
• Footnotes indicate the RSUs convert 1:1 to common stock, the RSUs were granted on June 6, 2025 and vested one year later, and some shares are held indirectly by an entity over which Coleman has voting and dispositive power.
• The filing was submitted on June 10, 2026 and does not indicate a late filing.

Context

• Transaction codes: M = exercise/conversion of derivative (here, RSU settlement); S = sale. The zero-dollar disposition reflects shares withheld or transferred to cover tax obligations upon RSU settlement; the open-market sale also covered tax obligations per the filing.
• These transactions reflect routine post-vesting tax withholding and related sales under an approved trading plan rather than an outright market-timing purchase decision.